Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment

American Journal of Roentgenology

Volumn 184, Issue 1, 2005, Pages 185-192

  Mengiardi, Bernard ^a   Honegger, Hanspeter ^b   Hodler, Juerg ^a   Exner, Ulrich G ^a   Csherhati, Miklos D ^c   Brühlmann, Werner ^b  

^a ORTHOPEDIC UNIVERSITY HOSPITAL BALGRIST   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c Orthopedic Practice   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW; BONE REMODELING; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET BONE DISEASE; PRIMARY BONE LYMPHOMA; PRIORITY JOURNAL; SOFT TISSUE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 11144307939     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.184.1.01840185     Document Type: Article

References (26)

1. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260
2. Mulligan ME, McRae GA, Murphey MD. Imaging features of primary lymphoma of bone. AJR 1999;173:1691-1697
3. Oberling C. Les reticulosarcomes et les reticuloendotheliosarcomes de la moelle osseuse (sarcoma d'Ewing). Bull del'Assoc Franc p l'Etude du Cancer 1928;17:259-296
4. Parker F, Jackson H. Primary reticulum cell sarcoma of bone. Surg Gynecol Obstet 1939;68:45-53
5. Clayton F, Butler JJ, Ayala AG, Ro JY, Zornoza J. Non-Hodgkin's lymphoma in bone: pathologic and radiologic features with clinical correlates. Cancer 1987;60:2494-2501
6. Baar J, Burkes RL, Bell R, Blackstein ME, Fernandes B, Langer F. Primary non-Hodgkin's lymphoma of bone: a clinicopathologic study. Cancer 1994;73:1194-1199
7. Stein ME, Kuten A, Gez E, et al. Primary lymphoma of bone: a retrospective study-experience at the Northern Israel Oncology Center (1979-2000). Oncology 2003;64:322-327
8. Sundaram M, McGuire MH. Computed tomography or magnetic resonance for evaluating the solitary tumor or tumor-like lesion of bone? Skeletal Radiol 1988;17:393-401
9. Panicek DM, Schwartz LH, Heelan RT, Caravelli JF. Non-neoplastic causes of high signal intensity at T2-weighted MR imaging after treatment for musculoskeletal neoplasm. Skeletal Radiol 1995;24:185-190
10. Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology 1987;164:243-245
11. Melamed JW, Martinez S, Hoffman CJ. Imaging of primary multifocal osseous lymphoma. Skeletal Radiol 1997;26:35-41
12. 67Ga scintigraphy and MRI. J Nucl Med 1999;40:387-393
13. Yuki M, Narabayashi I, Yamamoto K, et al. Multifocal primary lymphoma of bone: scintigraphy and MR findings before and after treatment. Radiat Med 2000;18:305-310
14. Mulligan ME, Kransdorf MJ. Sequestra in primary lymphoma of bone: prevalence and radiologic features. AJR 1993;160:1245-1248
15. Edeiken-Monroe B, Edeiken J, Kim EE. Radiologic concepts of lymphoma of bone. Radiol Clin North Am 1990;28:841-864
16. Hicks DG, Gokan T, O'Keefe RJ, et al. Primary lymphoma of bone: correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer 1995;75:973-980
17. Stiglbauer R, Augustin I, Kramer J, Schurawitzki H, Imhof H, Radaszkiewicz T. MRI in the diagnosis of primary lymphoma of bone: correlation with histopathology. J Comput Assist Tomogr 1992;16:248-253
18. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-691
19. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-116
20. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800
21. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-4471
22. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-433
23. Matthies A, Schuster SJ, Alavi A. Staging and monitoring response to treatment in primary non-Hodgkin's lymphoma of bone marrow using (18)F-fluorodeoxyglucose positron emission tomography. Clin Lymphoma 2001;1:303-306, discussion 307
24. Mac Vicar AD, Olliff JF, Pringle J, Pinkerton CR, Husband JE. Ewing sarcoma: MR imaging of chemotherapy-induced changes with histologic correlation. Radiology 1992;184:859-864
25. Lemmi MA, Fletcher BD, Marina NM, et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. AJR 1990;155:343-346
26. 67Ga scintigraphy and CT for prediction of outcome after treatment. J Nucl Med 2002;43:1295-1303